Eli Lilly's Stock Price Target Surpasses $1,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: NASDAQ.COM
- Analyst Optimism: The consensus analyst price target for Eli Lilly is currently $1,215, implying a potential upside of approximately 26% for investors buying today, reflecting strong bullish sentiment as 25 out of 30 analysts rate the stock as a buy.
- Strong Financial Performance: Eli Lilly achieved nearly 60% revenue growth in its most recent quarter, with sales projected to rise from $28.5 billion in 2022 to $65.2 billion by 2025, and profits tripling to $20.6 billion during this period, indicating robust fundamentals and promising growth prospects.
- Increased Valuation Appeal: Although Eli Lilly's price-to-earnings ratio is not cheap, its valuation has significantly improved compared to previous years, as the stock price has decreased while earnings have risen, making it a more attractive buy for investors.
- Long-Term Holding Potential: Given the company's strong fundamentals and growth outlook, Eli Lilly's stock is expected to rally past the $1,000 mark in the near term and has the potential for even greater long-term gains, positioning it as an excellent long-term investment choice.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 963.330
Low
950.00
Averages
1192
High
1500
Current: 963.330
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
Eli Lilly Shows Strong Growth Prospects
- Market Leadership: Eli Lilly has established itself as a leader in the rapidly growing GLP-1 drug market, with strong assets like Mounjaro and Zepbound driving significant growth in recent years, showcasing its competitive edge in the biopharmaceutical sector.
- Analyst Optimism: The current consensus price target for Eli Lilly's stock is $1,215, indicating a potential upside of approximately 26% for investors buying at the current price of $960, with 25 out of 30 analysts rating the stock as a buy, reflecting strong market confidence in its future performance.
- Attractive Valuation: Although Eli Lilly's price-to-earnings ratio is not cheap, its valuation has become more attractive due to a decline in stock price coupled with rising earnings, with sales projected to grow from $28.5 billion in 2022 to $65.2 billion by 2025, and profits tripling to $20.6 billion during this period.
- Long-Term Investment Potential: With excellent fundamentals and growth prospects, Eli Lilly's stock is expected to rally this year and potentially surpass the $1,000 mark, and in the long run, it could rise even higher, making it an excellent long-term holding choice.
See More
Three Growth Stocks to Consider Now
- Novo Nordisk's Challenges and Opportunities: Despite a 36% drop in share price over the past year, Novo Nordisk maintains strong profitability with a 33% gross margin and powerful assets like Ozempic and Wegovy, positioning it to benefit from growth in the GLP-1 market in the future.
- PDD Holdings' Market Potential: PDD Holdings has seen a 12% decline in stock price over the past year, yet reported a 12% revenue growth in the last three months of 2025, demonstrating resilience amid economic uncertainty, with Temu's popularity providing a foundation for future recovery.
- Intuit's Value Recovery: Although Intuit's stock has fallen 36% in the past year, its latest quarterly results show a 17% revenue increase, and its strong brand presence in accounting and tax software suggests it can leverage AI to enhance value moving forward.
- Investor Patience Rewarded: These three stocks currently have forward P/E ratios of 13, 8, and 15 respectively, indicating their investment value in the current market environment, with long-term holding potentially yielding significant returns for investors.
See More
Eli Lilly's Stock Price Target Surpasses $1,000
- Analyst Optimism: The consensus analyst price target for Eli Lilly is currently $1,215, implying a potential upside of approximately 26% for investors buying today, reflecting strong bullish sentiment as 25 out of 30 analysts rate the stock as a buy.
- Strong Financial Performance: Eli Lilly achieved nearly 60% revenue growth in its most recent quarter, with sales projected to rise from $28.5 billion in 2022 to $65.2 billion by 2025, and profits tripling to $20.6 billion during this period, indicating robust fundamentals and promising growth prospects.
- Increased Valuation Appeal: Although Eli Lilly's price-to-earnings ratio is not cheap, its valuation has significantly improved compared to previous years, as the stock price has decreased while earnings have risen, making it a more attractive buy for investors.
- Long-Term Holding Potential: Given the company's strong fundamentals and growth outlook, Eli Lilly's stock is expected to rally past the $1,000 mark in the near term and has the potential for even greater long-term gains, positioning it as an excellent long-term investment choice.
See More
Investor Sentiment on Viking Therapeutics Amid Market Volatility
- Optimistic Market Outlook: Despite a 15% decline in Viking Therapeutics' stock this year, Wall Street remains optimistic, projecting a 207% increase over the next 12 months with a price target of $92.33, reflecting confidence in its growth potential.
- Obesity Drug Development: Viking is developing the anti-obesity drug VK2735, currently undergoing two phase 3 clinical trials for obese patients with and without diabetes, where positive results could serve as a significant catalyst for stock price appreciation.
- Massive Market Demand: With obesity rates in the U.S. estimated at around 40% by the CDC and potentially as high as 70% according to recent studies, there exists a substantial unmet need in the obesity drug market that Viking aims to address with its products.
- Risks and Opportunities: While Viking faces competition from major pharmaceutical companies like Eli Lilly and Novo Nordisk, successful clinical trial outcomes for VK2735 could yield substantial market rewards, though investors should be wary of the stock's inherent volatility.
See More
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
Eli Lilly Shows Strong Growth Prospects
- Market Leadership: Eli Lilly has established itself as a leader in the rapidly growing GLP-1 drug market, with strong assets like Mounjaro and Zepbound driving significant growth in recent years, showcasing its competitive edge in the biopharmaceutical sector.
- Analyst Optimism: The current consensus price target for Eli Lilly's stock is $1,215, indicating a potential upside of approximately 26% for investors buying at the current price of $960, with 25 out of 30 analysts rating the stock as a buy, reflecting strong market confidence in its future performance.
- Attractive Valuation: Although Eli Lilly's price-to-earnings ratio is not cheap, its valuation has become more attractive due to a decline in stock price coupled with rising earnings, with sales projected to grow from $28.5 billion in 2022 to $65.2 billion by 2025, and profits tripling to $20.6 billion during this period.
- Long-Term Investment Potential: With excellent fundamentals and growth prospects, Eli Lilly's stock is expected to rally this year and potentially surpass the $1,000 mark, and in the long run, it could rise even higher, making it an excellent long-term holding choice.
See More
Three Growth Stocks to Consider Now
- Novo Nordisk's Challenges and Opportunities: Despite a 36% drop in share price over the past year, Novo Nordisk maintains strong profitability with a 33% gross margin and powerful assets like Ozempic and Wegovy, positioning it to benefit from growth in the GLP-1 market in the future.
- PDD Holdings' Market Potential: PDD Holdings has seen a 12% decline in stock price over the past year, yet reported a 12% revenue growth in the last three months of 2025, demonstrating resilience amid economic uncertainty, with Temu's popularity providing a foundation for future recovery.
- Intuit's Value Recovery: Although Intuit's stock has fallen 36% in the past year, its latest quarterly results show a 17% revenue increase, and its strong brand presence in accounting and tax software suggests it can leverage AI to enhance value moving forward.
- Investor Patience Rewarded: These three stocks currently have forward P/E ratios of 13, 8, and 15 respectively, indicating their investment value in the current market environment, with long-term holding potentially yielding significant returns for investors.
See More
Eli Lilly's Stock Price Target Surpasses $1,000
- Analyst Optimism: The consensus analyst price target for Eli Lilly is currently $1,215, implying a potential upside of approximately 26% for investors buying today, reflecting strong bullish sentiment as 25 out of 30 analysts rate the stock as a buy.
- Strong Financial Performance: Eli Lilly achieved nearly 60% revenue growth in its most recent quarter, with sales projected to rise from $28.5 billion in 2022 to $65.2 billion by 2025, and profits tripling to $20.6 billion during this period, indicating robust fundamentals and promising growth prospects.
- Increased Valuation Appeal: Although Eli Lilly's price-to-earnings ratio is not cheap, its valuation has significantly improved compared to previous years, as the stock price has decreased while earnings have risen, making it a more attractive buy for investors.
- Long-Term Holding Potential: Given the company's strong fundamentals and growth outlook, Eli Lilly's stock is expected to rally past the $1,000 mark in the near term and has the potential for even greater long-term gains, positioning it as an excellent long-term investment choice.
See More
Investor Sentiment on Viking Therapeutics Amid Market Volatility
- Optimistic Market Outlook: Despite a 15% decline in Viking Therapeutics' stock this year, Wall Street remains optimistic, projecting a 207% increase over the next 12 months with a price target of $92.33, reflecting confidence in its growth potential.
- Obesity Drug Development: Viking is developing the anti-obesity drug VK2735, currently undergoing two phase 3 clinical trials for obese patients with and without diabetes, where positive results could serve as a significant catalyst for stock price appreciation.
- Massive Market Demand: With obesity rates in the U.S. estimated at around 40% by the CDC and potentially as high as 70% according to recent studies, there exists a substantial unmet need in the obesity drug market that Viking aims to address with its products.
- Risks and Opportunities: While Viking faces competition from major pharmaceutical companies like Eli Lilly and Novo Nordisk, successful clinical trial outcomes for VK2735 could yield substantial market rewards, though investors should be wary of the stock's inherent volatility.
See More
